Nuvalent Inc.

1 in Phase 3

Quick facts

Phase 3 pipeline

Neladalkib (NVL-655) · Oncology
Neladalkib is a selective ALK (anaplastic lymphoma kinase) inhibitor that blocks ALK-driven signaling in cancer cells.

Phase 2 pipeline

Phase 1 pipeline

NVL-330

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: